Physician profile
Richard Casey
NPI 1326097759
$11,183.25
in general payments reported to CMS, 2019-2025
29 companies · $1,566 in 2025
The $1,566 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $838 · 2020: $194 · 2021: $194 · 2022: $461 · 2023: $7,420 · 2024: $509 · 2025: $1,566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,012 · Food and Beverage: $2,048 · Travel and Lodging: $1,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,011.85 |
| Food and Beverage | $2,047.84 |
| Travel and Lodging | $1,435.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,872.52 | 2022-2023 | Da Vinci Surgical System |
| Inspire Medical Systems, INC. | $1,125.11 | 2023-2025 | Inspire |
| Glaxosmithkline, LLC. | $703.63 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $622.94 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $238.88 | 2024-2025 | |
| Edwards Lifesciences Corporation | $155.56 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Inari Medical, INC. | $138.44 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.47 | 2025 | |
| United Therapeutics Corporation | $135.87 | 2022 | |
| Ethicon INC. | $133.16 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $120.55 | 2019-2025 | Uptravi |
| Livanova USA, INC. | $117.31 | 2022 | |
| Accelerate Diagnostics INC. | $107.39 | 2019 | |
| Genentech USA, INC. | $92.95 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $92.73 | 2019-2024 | Dupixent |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $78.24 | 2019 | |
| Merck Sharp & Dohme LLC | $67.67 | 2019-2025 | Winrevair |
| Grifols USA, LLC | $52.52 | 2019 | |
| Mylan Specialty L.P. | $35.52 | 2019-2024 | Yupelri |
| Insmed, INC. | $34.04 | 2019 | |
| Gilead Sciences, INC. | $26.54 | 2019 | |
| Viatris Specialty LLC | $23.67 | 2025 | Yupelri |
| Jazz Pharmaceuticals INC. | $20.75 | 2019 | |
| Allergan, INC. | $19.27 | 2020 | |
| Advanced Respiratory, INC | $15.90 | 2019 | |
| Shire North American Group INC | $15.62 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Casey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.